New contrast agents and technologies for myocardial contrast echocardiography

Daniele Rovai, Mark J Monaghan

Myocardial contrast echocardiography is a new method for evaluating myocardial perfusion. However, it relies on the marriage of two evolving technologies: ultrasound contrast agents and ultrasound imaging instrumentation. To date, these technologies have only been available to a limited number of researchers throughout the world. Within the next 12 months, both agents and specialised ultrasound instruments will be commercially available, making this new methodology open to widespread clinical application. Moreover, echocardiographic evaluation of myocardial perfusion should have a major role in the management of both chronic and acute ischaemic situations, myocardial infarction, and assessment of myocardial viability. This review examines the current and likely future status of both contrast agents and machines in this context. In addition, the probable clinical role of the methodology, as a potential replacement for nuclear techniques, is discussed.

In patients with coronary artery disease the study of myocardial perfusion is of great clinical relevance and is currently investigated by nuclear medicine techniques. Nuclear cardiology, however, is limited by contamination risks, by a limited availability of the equipment, and by considerable expense. Furthermore, the current role of nuclear medicine in cardiology is mainly confined to stable patients, while acutely ill patients rarely benefit from the information regarding myocardial perfusion.

An alternative method of studying myocardial perfusion is echocardiography following the injection of ultrasound contrast agents directly into the coronary circulation. This invasive approach, however, is limited to applications within the cardiac catheterisation laboratory. To overcome this limitation, investigators, pharmaceutical companies, and ultrasound industries have sought to develop a method that could achieve myocardial enhancement following peripheral venous injection of ultrasound contrast agents.

Wider use of this methodology might have an important impact on clinical cardiology, as myocardial perfusion could be evaluated non-invasively, requiring only the use of widely available ultrasound scanners that have been suitably adapted. Additionally, the study of myocardial perfusion by contrast echocardiography would make information on perfusion available to a large population of patients in different settings, from the emergency room to the outpatient clinic. This non-invasive approach to myocardial contrast echocardiography stands on three main pillars: new ultrasound contrast agents, new equipment, and clinical models for myocardial perfusion studies.

New contrast agents

Left ventricular cavity opacification can be obtained in the majority of patients after venous injection of lung-crossing agents such as Albunex (MBI, USA) and Levovist (Schering AG, Germany). However, neither of these agents is able to opacify the myocardium consistently using conventional signal processing and imaging modalities. In an attempt to visualise myocardial perfusion by intravenous Albunex injection, Villanueva et al injected dogs with a dose of this agent 10 times that previously used for diagnostic purposes. They selected microbubbles with a diameter larger than those used for conventional imaging and injected the contrast agent directly into the right atrial cavity. In addition, the animals were premedicated with diprydamole (to increase the ratio between coronary blood flow and cardiac output) and, finally, the echocardiographic images were digitally subtracted and colour coded. Although this approach allowed myocardial perfusion to be visualised in experimental animals, it cannot be used in the clinical setting.

Recently, a new generation of ultrasound contrast agents has been produced characterised by a prolonged persistence in the circulation. This persistence is related to the shell stability and the gases contained in the microbubbles, which have a higher density than air and a low solubility in blood. As shown in fig 1, the echo contrast effect generated by an agent spontaneously declines over time. This spontaneous decay in contrast intensity resembles that of radioisotopes and is mainly caused by the diffusion of the gases from the microbubbles in the surrounding medium. Thus, the microbubbles containing gases with low solubility in blood are characterised by a prolonged persistence and in vivo stability. A precursor of long persistence contrast agents is the agent EchoGen (Sonus Pharmaceutical, USA), which is based on dodecafluoropentane. This gas, in addition to the high density and low solubility in blood, displays an interesting property, a phase shift at 28-5°C. Thus, the agent is a fluid at room temperature and shifts to a gaseous phase at body temperature. Both cardiac cavities and the myocardium show contrast enhancement.
soon after venous administration. Later on, the contrast is washed out from the cardiac cavities whereas the myocardium maintains contrast enhancement, which can persist for several minutes. Recently, Grayburn et al.\(^6\) administered EchoGen intravenously in a canine model of acute coronary occlusion. Myocardial contrast echocardiography accurately defined the extent of the area of myocardium at risk and the infarct size. The main limitation of this agent is its potential toxicity; pulmonary artery pressure and pulmonary vascular resistance increase at high doses of contrast, while arterial oxygen satura-

tion and cardiac output decrease. A new formulation of this agent that allows a dense myocardial opacification without negative haemodynamic effects is under investigation.\(^7\)

Other new generation contrast agents are also characterised by an elevated in vivo stability but show the ability freely to cross the microcirculation in the absence of any tissue deposit. Compared with Albunex and Levovist, the behaviour of these agents is closer to that of intravascular free flowing tracers. These agents include perfluorohexane exposed microsized dextran albumin,\(^8\) FS069 (MBD),\(^9\) BR1 (Bracco Research, Switzerland),\(^10\) Imagent(r)US (Alliance Pharmaceutical Corp, USA),\(^11\) and Aerosomes.\(^12\) There are several others under investigation. The table illustrates many of the ultrasound contrast agents that are currently under development or available.

The intravenous injection of these agents results in an enhancement of the ultrasound signal in the ventricular cavities, which can last up to several minutes. During peak contrast enhancement of the left ventricular cavity, myocardial opacification has been observed with all agents. Myocardial contrast echo effect obtained by intravenous contrast echocardiography is expected to reflect the presence of microbubbles in the coronary circulation and thus myocardial perfusion. However, contrast enhancement of the myocardium could also be ascribed to a blooming effect induced by the huge number of microbubbles in the left ventricular cavity. Figure 2 shows that myocardial contrast effect does reflect true myocardial perfusion. In this dog, the left circumflex coronary artery was cannulated and perfused via a bypass with blood taken from the femoral artery (fig 3); a reservoir filled with blood was present in series in the bypassing circuit and delayed the arrival of blood in the circumflex perfusion territory.

After intravenous contrast administration, the myocardium perfused by the left anterior descending and the right coronary artery showed contrast enhancement (fig 2, left panel), while the myocardium perfused by the circumflex coronary artery showed a late contrast effect (fig 2, right panel). Furthermore, several experiments have been carried out in different laboratories that support the concept that myocardial echo enhancement after venous administration of the most recent generation of contrast agents reflects myocardial perfusion and may permit quantitative assessment of perfusion deficits.

Ultrasonic contrast agents available or under development

<table>
<thead>
<tr>
<th>Agent</th>
<th>Manufacturer</th>
<th>Type</th>
<th>Encapsulated Gas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albunex/Infason</td>
<td>Mallinckrodt (USA)</td>
<td>Albumin microsphere</td>
<td>Air</td>
</tr>
<tr>
<td>NC100,100</td>
<td>Nynoem (Norway)</td>
<td>Confidential</td>
<td>Air</td>
</tr>
<tr>
<td>Levovist</td>
<td>Schering (Germany)</td>
<td>Galactose palmitic acid</td>
<td>Air</td>
</tr>
<tr>
<td>Aerosomes/MRX115</td>
<td>ImmRx (USA)</td>
<td>Lipid microbubble</td>
<td>Perfluoropropane</td>
</tr>
<tr>
<td>Quantison (Depot)</td>
<td>Andarts (UK)</td>
<td>Albumin microsphere</td>
<td>Air</td>
</tr>
<tr>
<td>Echogen</td>
<td>Sunus (USA)</td>
<td>Phase-shift</td>
<td>Air</td>
</tr>
<tr>
<td>BY 963</td>
<td>Ivk-Gudsen (Germany)</td>
<td>Phospholipid</td>
<td>Dodecfluoropropane</td>
</tr>
<tr>
<td>FS069</td>
<td>MBI (USA)</td>
<td>Albumin microsphere</td>
<td>Air</td>
</tr>
<tr>
<td>BR1/Sonovox</td>
<td>Bracco (Switzerland)</td>
<td>Lysophosphatide</td>
<td>Pentfluoropentane</td>
</tr>
<tr>
<td>ImaGen/AF0150</td>
<td>Alliance (USA)</td>
<td>Buffered surfactant</td>
<td>SFE</td>
</tr>
<tr>
<td>Sonovist/SHU 563A</td>
<td>Schering</td>
<td>Cyanocrylate particle</td>
<td>Perfluorohexane</td>
</tr>
<tr>
<td>Echovist</td>
<td>Schering</td>
<td>Galactose</td>
<td>Air</td>
</tr>
</tbody>
</table>
New contrast agents and technologies for myocardial contrast echocardiography

New contrast agents do cause an increase in backscattered ultrasound intensity at the fundamental frequency (centre frequency of the transducer), the increment in intensity over the signal reflected from myocardial tissue is relatively small. This can make it difficult to evaluate the presence of the agent within the tissue. However, by examining specifically the signal content at the resonant frequency or its harmonic (especially the 2nd harmonic), there is much greater difference in signal level between tissue alone and tissue plus contrast. This makes detection of the presence of the contrast agent and its distribution much easier to appreciate.

While the tissue signal at the 2nd harmonic, which is achieved by transmitting at one frequency and then selectively receiving at double that frequency, is relatively low, the contrast agent generates a high amplitude signal, which is easier to detect. This technology is relatively easy to implement, either by modification to transducer design or by using broadband width transducers and digital input filtering. It has been shown to demonstrate myocardial perfusion as well as perfusion in other organs such as liver and kidney following low volume intravenous injections.15 It is unlikely that 2nd harmonic imaging is the final stage in the development of contrast agent imaging technology.

Recent studies have indicated that exposure of contrast microbubbles to diagnostic ultrasound fields results in their destruction. This clearly limits the potential effectiveness of ultrasound detection of perfusion. Methods to limit this phenomenon have been investigated including reducing the transducer output power, thereby decreasing spatial ultrasound intensity. Reductions in temporal ultrasound exposure may also be achieved by reconfiguring the echocardiography system so that intermittent rather than continuous imaging is performed.816 This means that only one frame of an echocardiographic image is generated every cardiac cycle (or every other cardiac cycle) rather than the normal imaging mode when approximately 30 frames per second are generated. By employing intermittent imaging, significant improvements in detection of myocardial perfusion have been demonstrated,17 as destruction of contrast microspheres is considerably reduced and microspheres that are destroyed are usually replenished before the next frame is created. One limitation of this technique is that a real time image is no longer displayed, which may have limitations for temporal analysis and visual appreciation of contrast appearance and disappearance. Improvements in image processing and display technology are likely to be employed to overcome these limitations.

However, it is also possible that the phenomenon of contrast microbubble destruction could be turned to advantage in the future, as contrast microbubbles could be used for drug delivery, using localised higher intensity ultrasound to destroy the microspheres and release a drug at desired sites. In addition, it may be possible to adjust ultrasound output power
levels, so that contrast microspheres are destroyed at exactly the same rate that they are replenished, within a given myocardial bed. Myocardial perfusion, which was occurring at a rate higher than the destruction rate, would result in a gradual increase in segment intensity, whereas lower levels of perfusion would mean that more microbubbles were being destroyed than being replenished and so intensity would decrease. In theory, this would allow this phenomenon to be used for measuring myocardial perfusion.

These technologies are still very much in their infancy, however, many ultrasound instrument manufacturers are introducing harmonic imaging as a facility on their systems. In addition, quantitative software is now available that allows analysis of the changes in 2nd harmonic (or other frequency characteristic) amplitudes before, during, and after contrast administration. Software that performs digital subtraction and colour coding on harmonic images is also being generated and this should create colour coded perfusion images, similar to those obtained by nuclear medicine studies. Pseudo-colour maps are often used to enhance the detection of spontaneous echo contrast in the left atrial cavity or appendage and such specific display modalities might favour the detection of low concentrations of contrast agent. Although no studies have so far compared grey scale with colour images in the detection of myocardial perfusion abnormalities, it is expected that colour coded images could allow a better detection of myocardial contrast enhancement.

A further advancement might be the use of so called functional images, where the colour represents the value of a functional parameter (fig 5). Each of these two images derives from the analysis of a series of frames and the colours represent the time from contrast injection into the aortic root up to myocardial contrast appearance. Under baseline conditions, the myocardium appears homogeneously red, while it turns towards yellow in the area perfused by a stenotic left circumflex coronary artery because of a delay in myocardial contrast appearance. Although these imaging modalities may favour the detection and localisation of myocardial perfusion abnormalities, it is not clear what the best parameter will be to study myocardial perfusion by intravenous contrast echocardiography.

Clinical models
Experimental studies have shown that myocardial contrast echocardiography can differentiate normal from severely hypoperfused myocardium; however, the absolute measurement of coronary blood flow by this technique is still limited by several factors.

It is foreseeable that the categories of patients who might benefit more from new echocardiographic contrast agents and technologies are those in whom a semiquantitative assessment of myocardial perfusion is sufficient for clinical decision making. These patients should ideally present a normal perfusion pattern in certain areas of the myocardium and a severe hypoperfusion in other areas. Examples are with either acute or chronic myocardial infarction.

In patients with acute infarction, the end points of contrast echocardiography should be to detect myocardial perfusion abnormalities, to quantify the spatial extent of these abnormalities, to establish the occurrence of myocardial reperfusion, and thus to predict the late recovery of left ventricular function.

In patients with previous infarction, contrast echocardiography should provide indices of myocardial viability, based on the hypothesis that myocardial echo contrast effect reflects microvascular integrity and thus viability. Finally, contrast echocardiography should be
New contrast agents and technologies for myocardial contrast echocardiography

compared with stress echocardiography with the end point of detecting myocardial ischaemia or viability. An example of combined stress and contrast echocardiography is shown in Fig 6, where Albunex was injected into the left coronary artery of a patient with previous infarction both at baseline and after intravenous dipyridamole infusion.

Conclusion
After the initial observation that it was possible to study myocardial perfusion by echocardiography, following injection of contrast agents into the coronary circulation, different investigators, pharmaceutical, and instrument companies have contributed towards a progressive advancement of knowledge in this field. Once the new generation of echo contrast agents and scanners are available, an acceleration in this process can be expected. The combination of these efforts will provide a non-invasive, non-nuclear assessment of myocardial perfusion, preserving the high spatial and temporal resolution of ultrasound, in addition, being available in real time in a number of different clinical arena.

New contrast agents and technologies for myocardial contrast echocardiography

Daniele Rovai and Mark J Monaghan

Heart 1997 78: 7-11
doi: 10.1136/hrt.78.Suppl_1.7

Updated information and services can be found at:
http://heart.bmj.com/content/78/Suppl_1/7.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/